Evaluation of Praziquantel Dosage for Treatment of Schistosomiasis in Brazil
Status:
Completed
Trial end date:
2008-05-01
Target enrollment:
Participant gender:
Summary
The primary objective of this project is to evaluate the efficacy and safety of praziquantel
60 mg/kg in the treatment of schistosomiasis, as compared to the standard 40 mg/kg therapy in
a representative community from a highly endemic area of schistosomiasis in Northeastern
Brazil. Cure rates, reduction in egg counts and proportions of reported side-effects in
children at the 10-19 y age-range with at least 100 eggs per gram of faeces will be compared
between regimens, aiming to evaluate the superiority of 60 mg/kg over the 40mg/kg dose
currently recommended by the WHO. Reinfection rates will also be evaluated aiming to improve
transmission control within the local health system, including re-treatment combined with
auxiliary control measures. Features related to the clinical, nutritional and immunological
status of the patients prior to treatment will also be investigated in association with the
outcome of praziquantel treatment.
Phase:
Phase 4
Details
Lead Sponsor:
Oswaldo Cruz Foundation
Collaborators:
Universidade Federal de Pernambuco World Health Organization